Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Establishes Essential Drug List Committee To Deal With Conflicts Of Interest

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's Ministry Of Health announced May 11 a national essential drug working committee to solve conflicts that arose while drafting the essential drug list

You may also be interested in...



Chinese Premier Wen Jiabao Allocates Healthcare Investment, But Essential Drug List Delayed Again

SHANGHAI - China's State Council issued additional healthcare reform plans July 8 to detail the goals of the country's ambitious reform plan. However, the release of the long-awaited essential drug list will be delayed to the end of this year, which was expected to be issued by June

Chinese Premier Wen Jiabao Allocates Healthcare Investment, But Essential Drug List Delayed Again

SHANGHAI - China's State Council issued additional healthcare reform plans July 8 to detail the goals of the country's ambitious reform plan. However, the release of the long-awaited essential drug list will be delayed to the end of this year, which was expected to be issued by June

China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D

One-third of small generic drug makers will be filtered out of the market in the next three to five years by the implementation of the new system, market research firm estimates.

Related Content

UsernamePublicRestriction

Register

SC071623

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel